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A total of 55 patients with histologically proven glioblastoma multiforme (total gross resection: n¼24, subtotal resection: n¼20,
stereotactic biopsy: n¼11) were treated with the combination of dacarbazine (D) (200mgm
 2) and fotemustine (F) (100mgm
 2)
and concomitant radiotherapy (2Gyday
 1, 5 days per week using limited fields up to 60Gy) to assess efficacy and toxicity of this
regimen. Survival (median survival, 12-, 18- and 24-month survival rates) and time to progression (median time to progression (TTP),
6-month progression-free survival) were analysed by Kaplan–Meier‘s method. A total of 268 (range 1–8, median: 5) cycles were
administered. Median survival is 14.5+ (range: 0.5–40+) months, and the 12-, 18- and 24-month survival rates are 58, 29 and 23%,
respectively. Median TTP from the start of D/F therapy is 9.5+ (range: 0.5–33+) months. The 6-month progression-free survival is
54%. Partial remissions were observed in 3.6%. Main toxicity was thrombocytopenia. Five patients were excluded from further D/F
application, four patients because of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of whole body
erythrodermia. One patient died because of septic fever during thrombocytopenia and leukopenia NCI-CTC grade 4 after the first
cycle. No other toxicities of NCI-CTC grade 3 or 4 occurred. The treatment is feasible in a complete outpatient setting and the
results of the D/F regimen justify further investigations with these compounds.
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Generally, the clinical course of patients with newly diagnosed
glioblastoma multiforme (GBM) is rapid and fatal with a median
survival of less than 1 year.
Standard therapy consists of surgical tumour reduction when
feasible, followed by radiotherapy up to a total dose of 60Gy. Both
strategies are associated with a significant survival benefit (Walker
et al, 1980; Simpson et al, 1993; Hess, 1999). Although a significant
increase in survival has been noted in two meta-analysis (Fine et al,
1993; Glioma Meta-analysis Trialists Group, 2002), the effect of
chemotherapy onto survival and progression has been discussed
controversially until the recent presentation of the meta-analysis of
the Glioma Meta-analysis Trialists Group (Glioma Meta-analysis
Trialists (GMT) Group, 2002). Therein, a significant increase in 1-
year survival from 40 to 46% is demonstrated. In addition,
chemotherapy consistently increases the proportion of long-term
survivors from less than 5% approximately 15–20% (Walker et al,
1980; Chang et al, 1983; Green et al, 1983; Fine et al, 1993; Salcman
et al, 1994; De Angelis et al, 1998).
The chemotherapeutic agent best studied in GBM has been
carmustine (Levin et al, 1990; Prados, 2000). To date, no other
drug has been proved to be superior. In comparison with
carmustine, the combination of procarbazine/lomustine/vincris-
tine failed to increase survival but resulted in more acute toxicity
(Prados et al, 1999).
However, improved treatment paradigms for GBM are continually
being sought. Currently, the substance investigated most eagerly is
temozolomide. An ongoing international, randomised trial will
reveal whether temozolomide produces a significant survival
advantage in newly diagnosed GBM (Stupp and Newlands, 2001),
after it has shown promise in several adjuvant trials (Newlands et al,
1992, 1996; Friedman et al, 1998; Stupp et al,2 0 0 0 ) .
In our present study, we concentrated on a more traditional
imidazotetrazine derivate, dacarbazine (D), in combination with
fotemustine (F), based on the following rationale.
D is a well-tolerated imidazotetrazine derivate (a synthetic
analogue of the naturally occurring purine precursor E-amino-1H-
imidazole-4-carboxamide) with proven efficacy in recurrent
gliomas (Mahaley, 1991). Furthermore, a synergistic effect among
the combination of D and F was observed in melanoma cell lines,
in patients with disseminated malignant melanoma and recurrent
GBM (Fischel et al, 1990; Aamdal et al, 1992; Avril et al, 1990). F,
(diethyl 1-(3-(2 chloroethyl) 3 nitrosoureido) ethyl phosphonate)
is an alkylating agent characterised by the grafting of a
phosphonoalanine group onto the nitrosourea radical with
consequent high lipophilia and a high brain permeability
coefficient. The improved diffusion through the cell membrane
and the blood–brain barrier implies favourable tissue distribution
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lon cerebral tumour lesions (Kayat et al, 1987). F yielded a 26%
response rate in recurrent malignant gliomas (Frenay et al, 1991)
and response rates between 25 and 28% in patients with cerebral
metastases of malignant melanoma (Jacquillat et al, 1990a,b). In
patients with unresectable GBM, a response rate of 27% could be
achieved by combining F with cisplatin and etoposid (Frenay et al,
2000). An own second-line study provides data of the D/F
combination in recurrent, nitrosourea-pretreated and previously
irradiated GBM, yielding a median survival of 45+ (range: 11–
142+) weeks (Fazeny-Do ¨rner et al, 2000).
These encouraging results prompted us to investigate the
combination of dacarbazine and fotemustine (D/F) with con-
comitant radiotherapy into first-line treatment with the aim to
assess efficacy and toxicity in newly diagnosed GBM.
PATIENTS AND METHODS
Eligibility criteria
Patients with newly diagnosed, histologically proven GBM, based
on the WHO classification (Kleihues and Sobin, 2000) after total
gross resection, subtotal resection or after stereotactic biopsy, were
eligible for inclusion into this study. For the evaluation of any
residual disease a cranial computed tomographic (CT) scan or
magnetic resonance imaging (MRI) had to be performed within
72h after neurosurgical procedure. Patients had to be aged
between 18 and 70 years, had to have a Karnofsky performance
score (KPS) X60% and a life expectancy of 48 weeks; patients
were not allowed to be under cytotoxic chemotherapy because of
concurrent malignancy. Other contraindications included any
known psychiatric disorder and pregnant or nursing women.
Adequate contraception was mandatory.
Radio- and chemotherapy had to be started within 10–14 days
after neurosurgical intervention in case of controlled wound
healing and missing signs of recent infection (white blood cell
counts, C-reactive protein and fibrinogen had to be within normal
range according to institutional standard).
Patients had to be on a stable dose of glucocorticoids (or no
glucocorticoids) for at least 1 week prior to study entry.
Furthermore, patients were required to have adequate liver
function (SGOT, SGPT and alkaline phosphatase levels less than
two times of institutional normal and bilirubin levels
o1.5mgdl
 1), renal (blood urea nitrogen or creatinine levels
o1.5 times of institutional normal) and bone marrow function
(leukocyte count 43000ml
–1 and a platelet count 4100000ml
 1)
before start of D/F therapy. All patients provided written informed
consent before study entry.
Study endpoints
The study end points were efficacy of the D/F regimen concomitant
to radiotherapy defined as response to chemotherapy, time to
progression (TTP), 6-month progression-free survival, median
survival, and 12-, 18- and 24-month survival rates.
Therapeutic protocol
Chemotherapy consisted of D in a dosage of 200mgm
 2 (diluted
in 250ml normal saline) and F in a dosage of 100mgm
 2 (diluted
in 250ml glucose 5%). Both solutions were protected from light
and were given intravenously in an outpatient setting. D was
administered over 30min, to avoid burning sensations during D
infusion, and 500ml normal saline was concomitantly adminis-
tered. At 30min after termination of D infusion, F was given for
over 60min. Cycles were repeated every 3 weeks. Treatment was
continued for a maximum of eight cycles, unless there was
progression of disease, unmanageable toxicity, fulfilled off-study
criteria or withdrawal of consent.
Modification of the doses or the dose interval of D/F was made
for haematologic toxicity based on the platelet and leukocyte count
on the day of the planned treatment. D/F treatment was postponed
up to a maximum of three consecutive weeks in case of
thrombocytopenia from the National Cancer Institue (NCI)
common toxicity criteria (CTC) (NCI, 1988) grade 1 and/or
leukopenia NCI-CTC grade 2 with weekly monitoring of blood cell
counts; otherwise the doses of D/F were decreased by 25% each.
Patients were excluded from further D/F treatment in the case of
thrombocytopenia NCI-CTC grade 2 lasting longer than 3 weeks or
immediately after thrombocytopenia or leukopenia NCI-CTC
grade X3. After exclusion from study patients were allowed to
be treated individually with previously unemployed drugs. Repeat
surgery was not considered routinely.
Antiemetics were administered to all patients before and after
chemotherapy application according to the institutional standard
(granisetron 5mg orally once a day from days 1–3 after D/F
therapy).
Doses of glucocorticoids (dexamethasone) were adjusted
according to the patients’ clinical status and were given in the
lowest dose necessary for neurologic stability. If the dosage was
increased to offset marked clinical deterioration, this was
considered when evaluating response, using the criteria of
MacDonald et al. (1990). Concomitantly ranititidin 300 mg orally
was given once daily. Anticonvulsants were used as medically
indicated.
Toxicity evaluation
Toxicity was evaluated according to the NCI’s common CTC (NCI,
1988) during routine controls in three-weekly intervals or, if
clinically indicated, in weekly intervals.
Monitoring of serum chemistry and blood cell counts was
performed prior to each cycle of therapy in three-weekly intervals.
In case of haematotoxicity necessitating a delay of chemotherapy
application, blood counts were performed in weekly intervals.
Patients were monitored with either cranial CT or MRI scan
after two, four, six and eight cycles of therapy in case of clinical
and neurological stability, and immediately when disease progres-
sion was suspected clinically.
Response evaluation
Response evaluation was based on MacDonald’s criteria (MacDo-
nald et al, 1990): complete response (CR) was defined as the
disappearance of all measurable disease with improved neurology
in the absence of corticoid therapy. Partial response (PR) was a
X50% decrease in tumour size with an improved or stable
neurology on stable or decreased dexamethasone dose. Stable
disease (SD) was a less than 50% decrease, or less than 25%
increase of the tumour size with an improved or stable neurology
on stable or decreased dexamethasone dose. Progressive disease
(PD) was a greater than 25% increase in tumour size or the
appearance of new lesions. Tumour evaluation was based on the
product of the two largest perpendicular diameters of the
contrasting lesion. If the tumour did not enhance, the diameters
of the hyperintense signal on T-2-weighted MRI images or of the
hypodense region on CT scans were used.
Off-study criteria
Patients were excluded from further D/F treatment if one of the
following was noted: (1) disease progression or recurrence as
documented by CT or MRI anytime after the completion of at least
one cycle of therapy as defined above; (2) severe and/or prolonged
haematotoxicity as defined above; (3) in case of a deteriorated and
unacceptable neurologic status; (4) in case of withdrawal of
consent.
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All analyses were done by intention to treat. The reference point
for median survival, 12-, 18- and 24-month survival, was the date
of neuropathologic diagnosis, and the end point was survival until
death, including deaths from causes not related to the disease.
Time to progression (TTP) was estimated from the first day of
D/F application to the first unfavourable event (e.g. radio-
graphically documented tumour recurrence or progression or
death). If a patient died without a scan to document disease status,
the TTP was measured until documented clinical worsening or
until the date of death.
Survival curves and TTP curves were constructed using
the Kaplan–Meier‘s nonparametric method, medians (and
their respective 95% confidence intervals) were calculated from
the Kaplan–Meier estimates (Kaplan and Meier, 1958; Young
et al, 1999). Statistical evaluations were performed with SPSS
version 10.0.7 program package. Data were analysed as of 31
January 2002.
RESULTS
A total of 55 patients (female/male: 16/39) with newly diagnosed,
histologically proven GBM were treated with D/F chemotherapy
between October 1998 and December 2001. In total, 24 patients had
gross total resection, 20 patients had a subtotal tumour resection
and in 11 patients stereotactic biopsy was performed. Concomitant
to chemotherapy all patients received radiotherapy up to a total
dose of 60Gy (30 2Gy single dose).
Median age was 44 (range: 18–68) years, the median KPS 1 week
after neurosurgical intervention was 90% (range: 60–100%).
Survival
At study evaluation 23 out of 55 (42%) patients are alive. Median
survival of all patients (Figure 1) is 72+ (range: 3–156) weeks
(¼14.5 months in median) with a 95% confidence interval of 28–
116 weeks. The 12-, 18- and 24-month survival rates after diagnosis
are 58, 29 and 23%, respectively.
Time to progression
The median TTP of all patients was 41+ (range: 3–144+) weeks
(¼9.5 months) (Figure 1).
Response to chemotherapy
A partial remission could be achieved in two patients (3.6%) with
subtotal resection, lasting for 12 weeks each. SD or no evidence of
disease lasting from 10 to 144+ weeks (median: 29 weeks) could be
achieved in 45 (81%) of the patients. Thereof, 24 patients had gross
total resection, 14 patients had subtotal resection and seven
patients had stereotactic biopsy.
SD or no evidence of disease lasting longer than 12 months was
observed in 12 (22%) patients. In these patients, glucocorticoids
could be tapered towards the end of radiotherapy and usually
stopped within 3 weeks after radiotherapy. Additionally, in these
patients the KPS improved at least by 10%.
Toxicity
In all, 55 patients received a total of 268 (range 1–8; median: 5)
cycles of D/F.
Major toxicity was thrombocytopenia. Four patients were
excluded from further D/F treatment, three because of thrombo-
cytopenia NCI-CTC grade 3 (after the second, fourth and sixth
cycle, respectively) and the other patient because of thrombo-
cytopenia of NCI-CTC grade 4 (after the eigth cycle of D/F), which
was accompanied by anaemia NCI-CTC grade 3, necessitating
substitution of platelets and two units of packed red cells.
One patient died owing to septic fever during combined
thrombocytopenia and leukopenia NCI-CTC grade 4 after the first
D/F application despite inward care, intravenous administration of
antibiotics, granulocyte colony-stimulating factors and substitu-
tion of platelets. Cranial CT before death showed stable disease of
the unresectable tumour.
Thrombocytopenia NCI-CTC grade 1 was observed in 11 cycles
(therapy was postponed for 1 week in seven cycles and for 2 weeks
in four cycles) and thrombocytopenia NCI-CTC grade 2 occurred
in 13 cycles (therapy was postponed for 1 week in five cycles, for 2
weeks in five cycles, and for 3 weeks in three cycles resulting in a
25% dose reduction of D/F). Leukopenia from NCI-CTC grade 1
occurred in six cycles (three cycles had to be postponed for 1
week) and from CTC grade 2 in six cycles, resulting in treatment
delay for 1 week in three cycles, for 2 weeks in one cycle and in a 3
weeks delay in two cycles, thus leading to a 25% dose reduction of
D/F.
A fifth patient was excluded from further therapy because of a
whole body erythordermia within 24 h after administration of the
second cycle of D/F.
Alopecia was evaluable in 55 patients. The most severe degree
was NCI-CTC grade 2 (n¼18).
Neither pulmonary toxicity nor any radiation necrosis was
observed during a follow-up period of 150 weeks. Under
standardised prophylactic antiemetics, patients did not suffer
from gastrointestinal toxicity. The main complaints of patients
concerned side effects from chronic glucocorticoid intake,
primarily the cushingoid appearance, myopathy and the vulner-
ability of the skin.
DISCUSSION
The adjuvant administration of D/F concomitant to radiotherapy
revealed to be feasible in a complete outpatient setting and yielded
a median survival of 14.5 months in patients with newly diagnosed
GBM. Our survival and TTP results range in the upper level of
those achieved in the limited number of available first-line
treatment strategies, which are summarized in Table 1. Therein,
the median TTP is 7 (range: 4.2–9.5) months and the median
Survival and TTP in weeks 
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Figure 1 Survival and TTP of patients with GBM after first-line therapy
with D and F:  , survival; K, time to progression (TTP).
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1997; Brandes et al, 1998; Friedman et al, 1998; Gruber et al, 1998;
Beauchesne et al, 1999; Frenay et al, 2000; Grossman et al,
2000; Stupp et al, 2000).
In particular, our study, administering the traditional imidazo-
tetrazinederivate, dacarbazine, is comparable with Stupp’s pre-
liminary study, administering the imidazotetrazinederivate
temozolomide (Stupp et al, 2000). Both imidazotertazinederivate
studies are similar concerning study design, extent of surgery and
the median Karnofsky performance score. Although the measur-
able partial response of 3.6% is discouraging, the definitive 12-
month survival achieved in our study is 58%, whereas the
estimated 12-month survival for the preliminary temozolomide
study has been reported to be 67%. It might be speculated whether
the younger median age of our patients might have contributed to
the favourable outcome. However, the recent meta-analysis of the
Glioma Meta-analysis Trialists Group (Glioma Meta-analysis
Trialists (GMT) Group, 2002) demonstrated that the relative effect
of chemotherapy on 1-year survival does not differ between
patients X40 years and those X60 years.
The 18-month survival is the usual marker for beneficial
influence of adjuvant chemotherapy (De Angelis et al, 1998).
It is documented in two studies of the synopsis summarised
in Table 1 and ranges between 15.4 and 28% and is 29% in our
study (Brandes et al, 1998; Beauchesne et al, 1999). Concerning
median survival, Gruber et al (1998) achieved 19.2 months with the
single agent carboplatinum. However, 18- and 24-month survival
rates are not reported in their study and a study populat-
ion smaller than 30 patients is known to preclude strong statistical
power.
An explanation for the efficacy of the D/F combination might be
the O6-alkyl synergy of D/F, and the augmentation thereof by the
excellent tissue distribution of F in cerebral tumour lesions on the
other hand (Jacquillat et al, 1990a,b; Lee et al, 1991; Aamdal et al,
1992; Frenay et al, 2000).
One case of fatal neutropenic fever after the first cycle of therapy
was unexpected. Neither advanced age nor a dismal pretherapeutic
KPS could explain this adverse event (Grant et al, 1995; Raymond
et al, 1996). No other case of serious toxicity than uncomplicated
leuco- and/or thrombocytopenia from NCI-CTC grades 3 and 4
Table 1 Synopsis of first-line chemotherapy trials in patients with newly diagnosed GBM
Author
No. of patients
with GBM
out of all patients
Agent and treatment
design
Median TTP
(months)
Median survival
(months) Remarks
Beauchesne et al (1999) 23/30 (Etoposide 100mgm
 2 d1–3)
q 4 weeks;  6
71 2
18-month survival: 15.4%
24-month survival: 4%
TTP + survival analysis for all 30
patients ‘near-concurrent’
radiotherapy
Brandes et al (1998) 56/56 (Carboplatin 350mgm
 2
d1,22,43+
7.5 12.5
18-month survival: 28%
24-month survival: 20%
Concurrent radiotherapy
(60Gy)
Teniposide 50mgm
 2 d1–3,
22–24,43–45 +
Carmustine 200mgm
 2)
q 8 weeks;  3
Fetell et al (1997) 33/33 (Paclitaxel 140–230mgm
 2 d1)
q 21 days;  3
n.e. 12.5 Radiotherapy at tumour
progression
Frenay et al (2000) 33/33 (Fotemustine 100mgm
 2 d1+ n.e. 10 Symptomatic unresectable
GBM Cisplatin 33mgm
 2 d1–3 +
Vepesid 75mgm
 2 d1–3)
q 28 days
Friedmann et al (1998) 33/33 (Temozolomide 200mgm
 2
d1–5, p.o.); q 28 days;  4
7m o n t h si nr e s p o n d i n g
patients (n=17)
12 months in responding
patients
Residual tumour mass after
surgery;
2 months in non-
responding patients
(n=16)
6 months in non-
responding patients
Chemotherapy before
radiotherapy
Friedmann et al (1999) 14/63 (Topotecan 2.6mgm
 2
over 72h) q weekly;  16
n.e. n.e. Chemotherapy before
radiotherapy
Partial response in 2/14 patients
Grossman et al (2000) 219/219 (1) BCNU+cisplatin
vs
(1): 5.4 (1): 10.7 No advantage from (1) over
(2)
(2) BCNU+radiotherapy (2): 4.2 (2): 11.2
Gruber et al (1998) 25/25 (carboplatin 600mgm
 2)
q 4 weeks;  4
8.4 19.2 Radiotherapy (60Gy) started
3–4 weeks after chemotherapy;
23/25 patients: KPS:100%
Stupp et al (2000) 45/45 (Temozolomide 75–200mgm
 2
d 5d) q 28 days
n.e Estimated 1-year
survival: 67%
Concomitant radiotherapy
This paper 55/55 (Dacarbazine 200mgm
 2 d1+ 9.5+ 14.5+ Concomitant radiotherapy
(60Gy) Fotemustine 100mgm
 2 d1)
q 21days;
18-month survival: 29%
24-month survival: 23% 61% of patients alive at study
evaluation
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well as in further 100 D/F applications in patients with recurrent
and lomustine pretreated GBM (Fazeny-Do ¨rner et al, 2000).
Otherwise, the toxicity of D/F was similar to the previously
reported experience with these compounds, thus making the
regimen suitable for completely outward administration (Jacquillat
et al, 1990a,b; Aamdal et al, 1992; Fazeny-Do ¨rner et al, 2000;
Raymond et al, 1996).
The results of the D/F regimen justify further investigations with
these compounds.
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